TORONTO--(BUSINESS WIRE)--Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced the formation of Ironshore Pharmaceuticals (America) Inc. (“IPA”), a wholly owned subsidiary, incorporated in Delaware, which will house the Company’s U.S. commercial operations. IPA will be responsible for the commercialization of HLD-200 (next-generation formulation of methylphenidate), HLD-100 (next-generation formulation of amphetamine), all existing and new development pipeline products as well as products in-licensed or acquired by Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland.
Help employers find you! Check out all the jobs and post your resume.
